Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 3/20 | 0.41 |
| ▸ | TK1 | P04183 | 2/20 | 0.40 |
| ▸ | TOP2A | P11388 | 4/20 | 0.38 |
| ▸ | TYMP | P19971 | 3/20 | 0.37 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260669 | 1.00 | TK2 (0.41) | TK2TK1TOP2ATYMPRNASE1 | |
| SCHEMBL1738250 | 0.93 | TK2 (0.42) | TK2TK1TOP2ATYMP | |
| SCHEMBL7065019 | 0.92 | TK2 (0.42) | TK2TK1TOP2ATYMP | |
| SCHEMBL7065021 | 0.92 | TK2 (0.42) | TK2TK1TOP2ATYMP | |
| SCHEMBL7901416 | 0.91 | DNPH1 (0.38) | TK2 | |
| SCHEMBL7901418 | 0.91 | DNPH1 (0.38) | TK2 | |
| SCHEMBL261288 | 0.91 | TK2 (0.47) | TK2TK1TOP2ATYMPRNASE1 | |
| SCHEMBL19812217 | 0.91 | TK2 (0.47) | TK2TK1TOP2ATYMPRNASE1 | |
| SCHEMBL261289 | 0.91 | TK2 (0.47) | TK2TK1TOP2ATYMPRNASE1 | |
| SCHEMBL7247156 | 0.91 | TK2 (0.41) | TK2TK1TOP2ATYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 761 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270024-B1 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180094260-A1 | EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS | KASTLE THERAPEUTICS, LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170355986-A1 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | KASTLE THERAPEUTICS, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9476051-B2 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9371530-B2 | Modulation of growth hormone receptor expression and insulin-like growth factor expression | ANTISENSE THERAPEUTICS LTD. (AU) | 2016-06-21 | — | — | US | disclosed |
| US-20150322429-A1 | SNPs OF APOLIPOPROTEIN B AND MODULATION OF THEIR EXPRESSION | COMERICA BANK | 2015-11-12 | — | — | US | disclosed |
| US-20150232838-A1 | EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS | COMERICA BANK | 2015-08-20 | — | — | US | disclosed |
| US-9084770-B2 | Modulation of insulin like growth factor I receptor expression in cancer | ANTISENSE THERAPEUTICS, LTD. (AU) | 2015-07-21 | — | — | US | disclosed |
| US-20150167008-A1 | ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| EP-2365094-B1 | Antisense modulation of PTP1B expression | ISIS PHARMACEUTICALS INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-6010906-A | NUCLEIC ACID HYBRID | ISIS PHARMACEUTICALS INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-6008344-A | AN OLIGONUCLEOTIDE TARGETED TO THE CODING REGION OF THE UNTRANSLATED REGIONS; THERAPY FOR ALZHEIMER'S DISEASE | ISIS PHARMACEUTICALS INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-6008048-A | AN OLIGONUCLEOTIDE FOR MODULATING EXPRESSION OF AN EARLY GROWTH RESPONSE-1 PROTEIN; CHELATING/EMULSIFYING AGENTS; ANTITUMOR/ANTIINFLAMMATORY/ANTICARCINOGENIC AGENTS; SURFACTANTS | ISIS PHARMACEUTICALS INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-6001992-A | OLIGONUCLEOTIDES WHICH PROMOTE APOPTOSIS; ANTICARCINOGENIC AGENTS, VIRICIDES, AND TREATMENT OF AUTOIMMUNE DISORDERS | ISIS PHARMACEUTICALS INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5998206-A | Antisense inhibiton of human G-alpha-12 expression | ISIS PHARMACEUTICALS INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5998148-A | Antisense modulation of microtubule-associated protein 4 expression | ISIS PHARMACEUTICALS INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5985663-A | AN ANTISENSE COMPOUND 8 TO 30 NUCLEOBASES IN LENGTH TARGETED TO A 5' UNTRANSLATED REGION OR 3' UNTRANSLATED REGION OF A NUCLEIC ACID ENCODING HUMAN INTERLEUKIN-15 | ISIS PHARMACEUTICALS INC. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5985664-A | ANTISENSE OLIGONUCLEOTIDES, TARGETED TO NUCLEIC ACIDS ENCODING SENTRIN | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| US-5981732-A | ANTISENSE OLIGONUCLEOTIDES WHICH TARGET THE EXPRESSION OF A G PROTEIN | ISIS PHARMACEUTICALS INC. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5977341-A | Antisense modulation of inhibitor-kappa B kinase-beta expression | ISIS PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |